RA
TVRD

Royce & Associates’s Tvardi Therapeutics TVRD Stock Holding History

Royce & Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,619
Closed -$340K – 948
2023
Q3 		$340K Hold
5,619
– – ﹤0.01% 841
2023
Q2 		$573K Hold
5,619
– – 0.01% 823
2023
Q1 		$993K Hold
5,619
– – 0.01% 763
2022
Q4 		$2.17M Sell
5,619
-330
-6% -$125K 0.02% 632
2022
Q3 		$2M Buy
5,949
+3,156
+113% +$1.14M 0.02% 625
2022
Q2 		$918K Sell
2,793
-307
-10% -$108K 0.01% 761
2022
Q1 		$1.36M Buy
3,100
+2,733
+745% +$1.12M 0.01% 775
2021
Q4 		$161K Sell
367
-54
-13% -$27.1K ﹤0.01% 950
2021
Q3 		$234K Buy
+421
New +$211K ﹤0.01% 962

Other funds holding TVRD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.17B AUM 42.44% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royce & Associates's TVRD Position: Q4 2023 in Review

Royce & Associates sold out of Tvardi Therapeutics (TVRD) in Q4 2023, closing a stake of 5,619 shares — an estimated $340K sold.

Royce & Associates first reported a position in TVRD in Q3 2021 and held it in 9 quarters. The position peaked at $2.17M in Q4 2022. 109 funds tracked by Wall St. Rank hold TVRD as of Q4 2023.

  • Royce & Associates reported no remaining Tvardi Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Royce & Associates sold 5,619 Tvardi Therapeutics shares in Q4 2023, an estimated $340K.
  • Royce & Associates first reported a position in Tvardi Therapeutics in Q3 2021 and held it in 9 quarters.
  • Royce & Associates's Tvardi Therapeutics position peaked at $2.17M in Q4 2022.
  • 109 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2023.

Based on Royce & Associates's 13F filing for Q4 2023, filed 12 Feb 2024.